TX-FLUENCE
16.11.2023 15:50:34 CET | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced it will have a major presence at MJBizCon, the leading cannabis industry conference. Fluence Cannabis Solutions Architect Casey Rivero will join a panel alongside Fluence customers to discuss how growers can maximize crop quality. In addition, the company is investing in connecting the cannabis community at this year’s conference, providing product demonstrations from Fluence’s line of leading LED lighting solutions as well as hosting a series of Grower Talks with Fluence experts at the company’s booth.
Moderated by MJBizDaily reporter Solomon Israel, Rivero’s session, entitled “Powering Through Market Conditions: How Growers in Established Markets are Doubling Down on Quality and Boosting Their Bottom-Line,” will provide growers with concrete steps they can take to navigate an uncertain market. Rivero, a former cannabis cultivator, will be joined by Travis Higginbotham, StateHouse vice president of cultivation; Chris Castle, COO and co-founder of Flora & Flame; Andrew Reich, division manager at SunMed Growers; and Tyler Smith, principal advisor at Smith Cultivations. The panel will take place from 10 to 10:40 a.m. PST on Thursday, Nov. 30 in room N259.
“Though I have had my own grows for years, I find myself learning every single day from the cultivators we collaborate with,” Rivero said. “I’m honored to sit beside some of the industry’s most successful and innovative growers and share our firsthand knowledge on what it takes to deliver the highest-quality product to the market.”
The company will also host a series of Grower Talks throughout the show at the Fluence booth (No. 43023). As part of the series, growers can learn about innovative HPS retrofitting strategies, intercanopy lighting solutions and other topics top of mind in the cannabis industry. Growers will have the opportunity to ask questions and solicit advice from experts in their field, including Taylor Kirk and Dr. Jason Matlock from Fluence's Horticulture Services division, as well as Dr. David Hawley, principal scientist and head of Fluence's Crop Research division. For a detailed list of sessions, including times and featured experts, visit Fluence’s social media the week of the show.
“MJBizCon is an opportunity for the brightest minds in cannabis to come together and share the latest innovations across every facet of the industry,” said Lorrie Schultz, senior vice president of marketing for Fluence. “We’re looking forward to amplifying the voices of our customers as well as sharing insights from our in-house cannabis experts to showcase how Fluence’s LED technology can help cultivators grow smarter, more efficiently and at the highest quality.”
Fluence experts will also demo products from the company’s suite of LED technologies, including its RAPTR, VYPR, SPYDR, RAZR and VYNE fixtures—each designed to make cannabis growers’ lives easier. According to Fluence and Cannabis Business Times’ recently released “State of the Cannabis Lighting Market” report, growers are addressing ongoing industry challenges by redoubling their focus on crop quality. Fluence’s LED technology and cultivation expertise helps cannabis growers throughout the world improve bud density and quality and drive financial success.
For more information on Fluence, stop by the company’s MJBizCon booth in Las Vegas, No. 43023, between Nov. 28 and Dec. 1—or visit www.fluence-led.com.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence-led.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116207472/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom